CY2014024I1 - Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] του hiv - Google Patents

Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] του hiv

Info

Publication number: CY2014024I1
Authority: CY; Cyprus
Prior art keywords: rase; integ; hiv; integration; inhibitory activity
Prior art date: 2005-04-28

Application number

CY2014024C

Other languages

English (en)

Other versions

CY2014024I2 (el

Original Assignee

Shionogi & Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-28

Filing date

2014-06-25

Publication date

2015-12-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2014024(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-25 Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.

2015-12-09 Publication of CY2014024I1 publication Critical patent/CY2014024I1/el

2015-12-09 Publication of CY2014024I2 publication Critical patent/CY2014024I2/el

Links

OHEKQGOBJIKKIF-AWEZNQCLSA-N (12as)-n-[(4-fluorophenyl)methyl]-7-hydroxy-6,8-dioxo-3,4,12,12a-tetrahydro-2h-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide Chemical class C([C@@H]1OCCCN1C(=O)C1=C(C2=O)O)N1C=C2C(=O)NCC1=CC=C(F)C=C1 OHEKQGOBJIKKIF-AWEZNQCLSA-N 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
230000010354 integration Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physiology (AREA)
Nutrition Science (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY2014024C 2005-04-28 2014-06-25 Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)κρασης [ενσωματασης] του hiv CY2014024I2 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2005131161		2005-04-28
JP2005312076		2005-10-27
PCT/US2006/016604 WO2006116764A1 (en)	2005-04-28	2006-04-28	Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (2)

Publication Number	Publication Date
CY2014024I1 true CY2014024I1 (el)	2015-12-09
CY2014024I2 CY2014024I2 (el)	2015-12-09

Family

ID=37215098

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
CY20131101061T CY1115151T1 (el)	2005-04-28	2013-11-27	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] του hiv
CY20141100201T CY1116331T1 (el)	2005-04-28	2014-03-13	Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv
CY2014024C CY2014024I2 (el)	2005-04-28	2014-06-25	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)κρασης [ενσωματασης] του hiv
CY20181100633T CY1120345T1 (el)	2005-04-28	2018-06-19	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης[ενσωματασης] toy hiv
CY20191100891T CY1122052T1 (el)	2005-04-28	2019-08-20	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv
CY20211100866T CY1124601T1 (el)	2005-04-28	2021-10-06	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20131101061T CY1115151T1 (el)	2005-04-28	2013-11-27	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] του hiv
CY20141100201T CY1116331T1 (el)	2005-04-28	2014-03-13	Παραγωγο πολυκυκλικης καρβαμοϋλοπυριδονης με ανασταλτικη ενεργοτητα της ιντεγκρασης του ηiv

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
CY20181100633T CY1120345T1 (el)	2005-04-28	2018-06-19	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης[ενσωματασης] toy hiv
CY20191100891T CY1122052T1 (el)	2005-04-28	2019-08-20	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv
CY20211100866T CY1124601T1 (el)	2005-04-28	2021-10-06	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] toy hiv

Country Status (29)

Country	Link
US (21)	US8129385B2 (el)
EP (9)	EP3187225B1 (el)
JP (2)	JP4295353B2 (el)
KR (4)	KR101504998B1 (el)
AU (1)	AU2006239177B8 (el)
BR (1)	BRPI0610030B8 (el)
CA (1)	CA2606282C (el)
CY (6)	CY1115151T1 (el)
DK (6)	DK3045206T3 (el)
EA (1)	EA014162B1 (el)
ES (7)	ES2446324T3 (el)
FI (1)	FIC20210017I1 (el)
FR (1)	FR14C0041I2 (el)
HK (4)	HK1107227A1 (el)
HU (6)	HUE056603T2 (el)
IL (4)	IL186555A (el)
LT (4)	LT3284520T (el)
LU (2)	LU92446I2 (el)
MA (1)	MA29460B1 (el)
MX (2)	MX302718B (el)
NL (2)	NL300676I2 (el)
NO (5)	NO339525B1 (el)
NZ (1)	NZ562339A (el)
PL (5)	PL3045206T3 (el)
PT (5)	PT3372281T (el)
SI (6)	SI3284520T1 (el)
TW (1)	TWI378931B (el)
VN (1)	VN34404A1 (el)
WO (1)	WO2006116764A1 (el)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101723949B (zh)	2003-12-24	2013-10-23	生物区科学管理控股有限公司	用于治疗呼吸道合胞体病毒感染的多环试剂
US7273859B2 (en) *	2004-05-12	2007-09-25	Bristol-Myers Squibb Company	HIV integrase inhibitors: cyclic pyrimidinone compounds
PL3045206T3 (pl)	2005-04-28	2018-08-31	Viiv Healthcare Company	Wielopierścieniowe pochodne karbamoilopirydonu wykazujące aktywność inhibitorową wobec integrazy HIV
AU2006244424B2 (en)	2005-05-10	2011-09-22	Merck Sharp & Dohme Corp.	HIV integrase inhibitors
JP5094725B2 (ja)	2005-10-04	2012-12-12	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ	Ｈｉｖインテグラーゼ阻害剤
TW200800988A (en)	2005-10-27	2008-01-01	Shionogi & Amp Co Ltd	Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
TWI423972B (zh)	2006-09-28	2014-01-21	Biota Scient Management	治療呼吸系融合細胞病毒感染之多環劑
EP2220076B1 (en)	2007-11-15	2012-01-18	Boehringer Ingelheim International GmbH	Inhibitors of human immunodeficiency virus replication
ES2402322T3 (es)	2007-11-15	2013-04-30	Gilead Sciences, Inc.	Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP2220046B1 (en)	2007-11-16	2014-06-18	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
EP2320908B9 (en) *	2008-07-25	2014-06-18	VIIV Healthcare Company	Dolutegravir Prodrugs
WO2010011818A1 (en) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
WO2010011815A1 (en) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
EP2330902B1 (en) *	2008-07-25	2012-11-14	GlaxoSmithKline LLC	Chemical compounds
KR101695807B1 (ko) *	2008-07-25	2017-01-13	비이브 헬쓰케어 컴퍼니	화합물
ES2763540T3 (es) *	2008-12-11	2020-05-29	Viiv Healthcare Co	Intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona
US8624023B2 (en) *	2008-12-11	2014-01-07	Shionogi & Co., Ltd.	Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8710249B2 (en)	2008-12-11	2014-04-29	Shionogi & Co., Ltd.	Maltol ether processes and intermediates
AU2014277831C1 (en) *	2008-12-11	2022-10-06	Shionogi & Co. Ltd.	Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (zh)	2009-03-26	2016-01-21	鹽野義製藥股份有限公司	哌喃酮與吡啶酮衍生物之製造方法
LT2444400T (lt)	2009-06-15	2018-06-11	Shionogi & Co., Ltd.	Pakeistasis policiklinis karbamoilpiridono darinys
WO2011011483A1 (en) *	2009-07-22	2011-01-27	Glaxosmithkline Llc	Chemical compounds
AU2010305805B2 (en)	2009-10-13	2014-04-03	Elanco Animal Health Ireland Limited	Macrocyclic integrase inhibitors
TR201807704T4 (tr)	2010-01-27	2018-06-21	Viiv Healthcare Co	Anti-viral tedavi.
AU2014202406C1 (en) *	2010-01-27	2019-03-07	Viiv Healthcare Company	Antiviral therapy
AU2014202404C1 (en) *	2010-01-27	2022-06-23	Viiv Healthcare Company	Antiviral therapy
TWI508968B (zh) *	2010-02-08	2015-11-21	Biota Scient Management	用於治療呼吸道融合性病毒感染的化合物
TW201139437A (en)	2010-02-26	2011-11-16	Japan Tobacco Inc	1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative and use of the same as HIV integrase inhibitor
TWI582097B (zh) *	2010-03-23	2017-05-11	Ｖｉｉｖ醫療保健公司	製備胺甲醯吡啶酮衍生物及中間體之方法
JP5739517B2 (ja)	2010-04-02	2015-06-24	ヤンセン・アールアンドデイ・アイルランド	大環状インテグラーゼ阻害剤
WO2011129095A1 (ja) *	2010-04-12	2011-10-20	塩野義製薬株式会社	インテグラーゼ阻害活性を有するピリドン誘導体
WO2012006104A2 (en)	2010-06-28	2012-01-12	Academia Sinica, Taiwan	Compounds and methods for treating tuberculosis infection
CN103154004B (zh)	2010-08-05	2016-07-06	盐野义制药株式会社	具有hiv整合酶抑制活性的化合物的制造方法
TWI577377B (zh) *	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
TR201810736T4 (tr)	2010-09-24	2018-08-27	Shionogi & Co	Substitüe polisiklik karbamoil piridon derivatı ön-ilacı.
US8796303B2 (en)	2010-11-26	2014-08-05	Biota Scientific Management Pty Ltd.	Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) *	2011-05-03	2014-07-31	Concert Pharmaceuticals Inc.	Carbamoylpyridone derivatives
EP2742051B1 (en)	2011-09-14	2016-10-12	Mapi Pharma Limited	Amorpous form of the dolutegravir sodium salt
CA2851218A1 (en) *	2011-10-12	2013-04-18	Shionogi & Co., Ltd.	Polycyclic pyridone derivative having integrase-inhibiting activity
CN104135859B (zh)	2011-12-28	2017-06-27	全球血液疗法公司	取代的苯甲醛化合物及其用于增加组织氧合的方法
US9012450B2 (en)	2011-12-28	2015-04-21	Global Blood Therapeutics, Inc.	Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9714243B2 (en)	2012-12-17	2017-07-25	Merck Sharp & Dohme Corp.	4-pyridinonetriazine derivatives as HIV integrase inhibitors
MD4736C1 (ro) *	2012-12-21	2021-07-31	Gilead Sciences, Inc.	Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
AR094311A1 (es) *	2012-12-27	2015-07-22	Japan Tobacco Inc	Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv
CA2897137A1 (en)	2013-02-18	2014-08-21	Ratiopharm Gmbh	Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en)	2013-02-18	2014-08-20	Ratiopharm GmbH	Solid pharmaceutical dosage form of dolutegravir
WO2014128545A2 (en)	2013-02-19	2014-08-28	Aurobindo Pharma Limited	An improved process for the preparation of dolutegravir
PE20160078A1 (es)	2013-03-15	2016-03-02	Global Blood Therapeutics Inc	Compuestos y sus usos para modular la hemoglobina
US9422279B2 (en)	2013-03-15	2016-08-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en)	2013-03-15	2017-03-28	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en)	2013-03-15	2017-10-31	Global Blood Therapeutics, Inc.	Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
MY183637A (en)	2013-03-15	2021-03-04	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
AP2015008721A0 (en)	2013-03-15	2015-09-30	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en)	2013-03-15	2014-09-18	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en)	2013-03-15	2018-10-16	Global Blood Therapeutics, Inc.	Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014172188A2 (en)	2013-04-16	2014-10-23	Merck Sharp & Dohme Corp.	4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
EP3008044B1 (en) *	2013-06-13	2018-11-21	Merck Sharp & Dohme Corp.	Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3016935B1 (en)	2013-07-04	2018-09-05	Hetero Research Foundation	Process for the preparation of intermediate of dolutegravir
NO2865735T3 (el) *	2013-07-12	2018-07-21
HUE037347T2 (hu)	2013-07-12	2018-08-28	Gilead Sciences Inc	Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
US9856270B2 (en) *	2013-07-17	2018-01-02	Ratiopharm Gmbh	Dolutegravir salts
WO2015019310A1 (en)	2013-08-07	2015-02-12	Mylan Laboratories Ltd	Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) *	2013-09-23	2015-03-26	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
ES2768658T3 (es)	2013-09-27	2020-06-23	Merck Sharp & Dohme	Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del VIH
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
WO2015089847A1 (en) *	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015092752A1 (en)	2013-12-20	2015-06-25	Mylan Laboratories Ltd.	Novel crystalline form of dolutegravir sodium
US9808428B2 (en)	2014-01-14	2017-11-07	Board Of Regents Of The University Of Nebraska	Compositions and methods for the delivery of therapeutics
US9856271B2 (en)	2014-01-21	2018-01-02	Laurus Labs Limited	Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
PT3102208T (pt)	2014-02-07	2021-04-05	Global Blood Therapeutics Inc	Polimorfos cristalinos da base livre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3 il)metoxi)benzaldeído
WO2015138933A1 (en)	2014-03-13	2015-09-17	Assia Chemical Industries Ltd.	Solid state forms of dolutegravir sodium
WO2015139591A1 (zh) *	2014-03-19	2015-09-24	杭州普晒医药科技有限公司	德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (en)	2014-03-20	2015-09-24	Cipla Limited	Pharmaceutical composition
ZA201503540B (en) *	2014-05-20	2016-10-26	Cipla Ltd	Process for preparing polycyclic carbamoyl pyridone derivatives
TW201613936A (en) *	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (el)	2014-06-20	2018-06-23
TWI677489B (zh) *	2014-06-20	2019-11-21	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
US10011613B2 (en)	2014-08-22	2018-07-03	Shionogi & Co., Ltd.	Polycyclic pyridone derivative having integrase inhibitory activity
EP3203995A4 (en)	2014-10-09	2019-05-15	Board of Regents of the University of Nebraska	COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
WO2016092527A1 (en) *	2014-12-12	2016-06-16	Sun Pharmaceutical Industries Limited	A process for the preparation of dolutegravir
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3045461A1 (en)	2015-01-16	2016-07-20	LEK Pharmaceuticals d.d.	Processes for preparing dolutegravir and analogues thereof
KR20170113650A (ko)	2015-02-06	2017-10-12	밀란 래버러토리스 리미티드	돌루테그라비어의 제조 방법
CZ201599A3 (cs)	2015-02-13	2016-08-24	Zentiva, K.S.	Pevné formy solí dolutegraviru a způsob jejich přípravy
EP3285582B1 (en) *	2015-03-26	2020-11-11	Merck Sharp & Dohme Corp.	Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr)	2015-03-30	2018-02-06	Global Blood Therapeutics Inc	Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PL3277691T3 (pl)	2015-04-02	2019-07-31	Gilead Sciences, Inc.	Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
EP4219508B1 (en) *	2015-04-28	2024-06-05	Shionogi & Co., Ltd	Substituted polycyclic pyridone derivative and prodrug thereof
WO2016187788A1 (en)	2015-05-25	2016-12-01	Merck Sharp & Dohme Corp.	Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs)	2015-08-04	2017-02-15	Zentiva, K.S.	Pevné formy amorfního dolutegraviru
WO2017029642A2 (en)	2015-08-19	2017-02-23	Laurus Labs Private Limited	Novel polymorphs of dolutegravir and salts thereof
BR102016026127A2 (pt)	2015-11-09	2017-05-16	Gilead Sciences Inc	composições terapêuticas para o tratamento do vírus da imunodeficiência humana
WO2017087257A1 (en)	2015-11-17	2017-05-26	Merck Sharp & Dohme Corp.	Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
TW201731509A (zh)	2015-12-04	2017-09-16	全球血液治療公司	針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
US10544155B2 (en)	2015-12-15	2020-01-28	Merck Sharp & Dohme Corp.	Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
PT3394069T (pt)	2015-12-21	2019-08-30	Lupin Ltd	Processo para a preparação de inibidores de integrase de vih
AR108435A1 (es)	2016-05-12	2018-08-22	Global Blood Therapeutics Inc	Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
WO2017208105A1 (en)	2016-05-30	2017-12-07	Lupin Limited	Novel crystalline form of dolutegravir sodium
WO2017223280A2 (en) *	2016-06-23	2017-12-28	Viiv Healthcare Company	Compositions and methods for the delivery of therapeutics
BR112019002132A2 (pt)	2016-08-08	2019-05-14	Hetero Labs Limited	composições anti-retrovirais
EP3496719B1 (en)	2016-08-08	2023-06-14	Hetero Labs Limited	A multi-class anti-retroviral composition
AU2017310526B2 (en) *	2016-08-12	2021-08-12	Edwin J. Iwanowicz	Protein kinase regulators
WO2018042332A1 (en)	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinations and uses and treatments thereof
EP3515438B1 (en) *	2016-09-21	2022-03-02	Merck Sharp & Dohme Corp.	Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh)	2016-10-12	2023-08-16	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) *	2016-12-02	2019-06-02	Merck Sharp & Dohme	مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
RU2749043C2 (ru)	2016-12-02	2021-06-03	Мерк Шарп И Доум Корп.	Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
WO2018109786A1 (en)	2016-12-16	2018-06-21	Cipla Limited	Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en)	2017-01-26	2018-08-02	Merck Sharp & Dohme Corp.	Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2018149608A1 (en) *	2017-02-16	2018-08-23	Sandoz Ag	Crystalline forms of cabotegravir sodium
EP3363802B1 (en) *	2017-02-16	2019-11-20	Sandoz AG	Crystalline form of cabotegravir sodium
US20200138845A1 (en) *	2017-07-18	2020-05-07	Viiv Healthcare Company	Combination Drug Therapy
US11564921B2 (en)	2017-07-21	2023-01-31	Viiv Healthcare Company	Regimens for treating HIV infections and AIDS
US20210040116A1 (en)	2017-09-07	2021-02-11	Cipla Limited	New Polymorphs of Dolutegravir Sodium
EP3693373A4 (en)	2017-10-06	2021-11-03	Shionogi & Co., Ltd.	PROCESS FOR THE STEREOSELECTIVE PRODUCTION OF SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES
US11839623B2 (en)	2018-01-12	2023-12-12	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and formulations thereof
WO2019159199A1 (en)	2018-02-16	2019-08-22	Cipla Limited	Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
WO2019199756A1 (en)	2018-04-09	2019-10-17	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and formulations thereof
CN110526930B (zh)	2018-05-23	2022-06-03	莫云芬	抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
TWI820141B (zh) *	2018-05-31	2023-11-01	日商鹽野義製藥股份有限公司	衍生物
MX2020012185A (es) *	2018-05-31	2021-01-29	Shionogi & Co	Derivado policiclico de piridona.
KR20210015922A (ko)	2018-05-31	2021-02-10	시오노기 앤드 컴파니, 리미티드	다환성 카바모일피리돈 유도체
US11634431B2 (en)	2018-07-12	2023-04-25	Laurus Labs Limited	Process for purification of protected polycyclic carbamoylpyridone derivatives
US11014884B2 (en)	2018-10-01	2021-05-25	Global Blood Therapeutics, Inc.	Modulators of hemoglobin
CA3117453A1 (en)	2018-10-22	2020-04-30	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and nanoformulations thereof
WO2020197991A1 (en)	2019-03-22	2020-10-01	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (ru) *	2019-06-03	2020-03-18	Андрей Александрович Иващенко	Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en)	2019-06-20	2020-12-24	Bell Helicopter Textron Inc.	Low-drag rotor blade extension
US11248005B2 (en)	2019-07-08	2022-02-15	Lupin Limited	Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
WO2021107066A1 (ja)	2019-11-28	2021-06-03	塩野義製薬株式会社	インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
TW202135815A (zh)	2019-12-09	2021-10-01	美商Ｖｉｉｖ醫療保健公司	醫藥組合物
CN115151545A (zh) *	2020-02-24	2022-10-04	吉利德科学公司	用于治疗hiv感染的四环化合物
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4208169A1 (en)	2020-09-01	2023-07-12	VIIV Healthcare Company	Combination of cabotegravir and levonorgestrel
WO2022079739A1 (en)	2020-10-14	2022-04-21	Cipla Limited	Fixed dose compositions of cabotegravir and rilpivirine
WO2022125378A2 (en)	2020-12-07	2022-06-16	Viiv Healthcare Company	Combination therapy
MX2023008137A (es)	2021-01-19	2023-07-21	Gilead Sciences Inc	Compuestos de piridotriazina sustituidos y usos de estos.
TW202313623A (zh)	2021-06-03	2023-04-01	大陸商江蘇恆瑞醫藥股份有限公司	具有整合酶抑制活性的吡啶酮化合物及其藥用用途
CN114230579A (zh) *	2021-11-12	2022-03-25	南京艾迪医药科技有限公司	多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (en)	2021-12-03	2023-06-08	Viiv Healthcase Company	Process of synthesizing (r)-3-aminobutan-1-ol

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3959316A (en) *	1972-03-13	1976-05-25	Snam Progetti S.P.A.	Procedure for propylene oxide synthesis
JPH0296506A (ja) *	1988-09-30	1990-04-09	Daicel Chem Ind Ltd	除草剤組成物
JP2551472B2 (ja)	1988-10-18	1996-11-06	ダイセル化学工業株式会社	５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja)	1988-10-18	1996-09-11	ダイセル化学工業株式会社	５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
CN1128790C (zh)	1997-12-22	2003-11-26	法玛西雅厄普约翰美国公司	用作抗病毒剂的4－羟基喹啉－3－甲酰胺和酰肼化合物
AU2001262732A1 (en) †	2000-06-14	2001-12-24	Shionogi And Co., Ltd.	Inhibitor for enzyme having two divalent metal ions as active centers
US6580562B2 (en)	2000-07-24	2003-06-17	Yazaki Corporation	On-vehicle display unit
US6384263B1 (en)	2000-08-04	2002-05-07	E. I. Du Pont De Nemours And Company	Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
ES2287170T3 (es)	2000-10-12	2007-12-16	MERCK & CO., INC.	Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa.
JP2003032772A (ja)	2001-07-12	2003-01-31	Foster Electric Co Ltd	耳掛け式イヤホン
KR20100087209A (ko)	2001-08-10	2010-08-03	시오노기세이야쿠가부시키가이샤	항바이러스제
RS51542B (sr)	2001-10-26	2011-06-30	Istituto Di Ricerche Di Biologia Molecolare P.Angeletti Spa.	N-supstituisani hidroksipirimidinon karboksamidni inhibitori hiv integraze
WO2003035076A1 (en)	2001-10-26	2003-05-01	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
DE60315796T2 (de)	2002-01-17	2008-06-05	Merck & Co., Inc.	Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
AU2003248872A1 (en)	2002-07-09	2004-01-23	Bristol-Myers Squibb Company	Hiv integrase inhibitors
WO2004024693A1 (ja)	2002-08-13	2004-03-25	Shionogi & Co., Ltd.	Ｈｉｖインテグラーゼ阻害活性を有するヘテロ環化合物
US7517532B2 (en) *	2002-09-11	2009-04-14	Merck & Co., Inc.	Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
MXPA05007010A (es)	2002-12-27	2005-08-18	Angeletti P Ist Richerche Bio	Tetrahidro-4h-pirido[1,2-a]pirimidinas y compuestos relacionados utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana.
US6960680B2 (en)	2003-01-08	2005-11-01	Rhodia Chirex, Inc.	Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja)	2003-02-10	2004-09-02	Shionogi & Co Ltd	含窒素複素環抗ウイルス剤
EP1622615A4 (en)	2003-05-13	2009-02-18	Smithkline Beecham Corp	INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
AU2003273190A1 (en) *	2003-08-12	2005-02-25	Rachel Beijer	Scheduled message service
TW200510425A (en) *	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja)	2003-10-31	2010-08-25	オリンパス株式会社	内視鏡装置
BRPI0507628A (pt)	2004-02-11	2007-07-03	Smithkline Beecham Corp	composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
EP1725554A1 (en)	2004-03-09	2006-11-29	Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.	Hiv integrase inhibitors
CA2557785A1 (en)	2004-03-09	2005-10-06	Merck & Co. Inc.	Hiv integrase inhibitors
WO2005110415A1 (en)	2004-05-07	2005-11-24	Merck & Co., Inc.	Hiv integrase inhibitors
WO2006066414A1 (en)	2004-12-23	2006-06-29	Virochem Pharma Inc.	Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
ATE516026T1 (de) *	2005-02-21	2011-07-15	Shionogi & Co	Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
CN101146811B (zh)	2005-03-31	2012-01-11	P.安杰莱蒂分子生物学研究所	Hiv整合酶抑制剂
PL3045206T3 (pl) *	2005-04-28	2018-08-31	Viiv Healthcare Company	Wielopierścieniowe pochodne karbamoilopirydonu wykazujące aktywność inhibitorową wobec integrazy HIV
JP2005312076A (ja)	2005-05-26	2005-11-04	Olympus Corp	電子撮像装置
EP1910363A4 (en)	2005-08-04	2010-05-26	Glaxosmithkline Llc	INHIBITORS OF HIV INTEGRASE
TW200800988A (en)	2005-10-27	2008-01-01	Shionogi & Amp Co Ltd	Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity

2006
- 2006-04-28 PL PL16154531T patent/PL3045206T3/pl unknown
- 2006-04-28 SI SI200632344T patent/SI3284520T1/sl unknown
- 2006-04-28 PL PL06758843T patent/PL1874117T3/pl unknown
- 2006-04-28 ES ES12159082.2T patent/ES2446324T3/es active Active
- 2006-04-28 EP EP17156762.1A patent/EP3187225B1/en active Active
- 2006-04-28 CA CA2606282A patent/CA2606282C/en active Active
- 2006-04-28 JP JP2008509227A patent/JP4295353B2/ja active Active
- 2006-04-28 WO PCT/US2006/016604 patent/WO2006116764A1/en active Application Filing
- 2006-04-28 VN VN201300151A patent/VN34404A1/vi unknown
- 2006-04-28 ES ES17195280T patent/ES2743531T3/es active Active
- 2006-04-28 PT PT181666215T patent/PT3372281T/pt unknown
- 2006-04-28 EA EA200702080A patent/EA014162B1/ru active Protection Beyond IP Right Term
- 2006-04-28 US US11/919,386 patent/US8129385B2/en active Active
- 2006-04-28 ES ES16154531T patent/ES2667868T5/es active Active
- 2006-04-28 NZ NZ562339A patent/NZ562339A/en unknown
- 2006-04-28 KR KR1020137028203A patent/KR101504998B1/ko active IP Right Grant
- 2006-04-28 ES ES12159079.8T patent/ES2567197T3/es active Active
- 2006-04-28 ES ES17156762T patent/ES2906792T3/es active Active
- 2006-04-28 EP EP17195276.5A patent/EP3284519A1/en active Pending
- 2006-04-28 MX MX2007013351A patent/MX302718B/es active IP Right Grant
- 2006-04-28 SI SI200632268T patent/SI3045206T1/en unknown
- 2006-04-28 DK DK16154531.4T patent/DK3045206T3/en active
- 2006-04-28 EP EP18166621.5A patent/EP3372281B1/en active Active
- 2006-04-28 KR KR1020147017235A patent/KR101580310B1/ko active IP Right Grant
- 2006-04-28 AU AU2006239177A patent/AU2006239177B8/en active Active
- 2006-04-28 DK DK06758843.4T patent/DK1874117T3/da active
- 2006-04-28 HU HUE18166621A patent/HUE056603T2/hu unknown
- 2006-04-28 PT PT67588434T patent/PT1874117E/pt unknown
- 2006-04-28 SI SI200632418T patent/SI3187225T1/sl unknown
- 2006-04-28 EP EP17156763.9A patent/EP3187226A1/en not_active Withdrawn
- 2006-04-28 PT PT161545314T patent/PT3045206T/pt unknown
- 2006-04-28 PL PL18166621T patent/PL3372281T3/pl unknown
- 2006-04-28 TW TW095115285A patent/TWI378931B/zh active
- 2006-04-28 EP EP12159082.2A patent/EP2465580B1/en active Active
- 2006-04-28 PT PT17195280T patent/PT3284520T/pt unknown
- 2006-04-28 PL PL12159082T patent/PL2465580T3/pl unknown
- 2006-04-28 PL PL17195280T patent/PL3284520T3/pl unknown
- 2006-04-28 KR KR1020157036007A patent/KR101848819B1/ko active IP Right Review Request
- 2006-04-28 DK DK18166621.5T patent/DK3372281T3/da active
- 2006-04-28 PT PT121590822T patent/PT2465580E/pt unknown
- 2006-04-28 SI SI200631703T patent/SI1874117T1/sl unknown
- 2006-04-28 DK DK17156762.1T patent/DK3187225T3/da active
- 2006-04-28 ES ES06758843.4T patent/ES2437268T3/es active Active
- 2006-04-28 EP EP06758843.4A patent/EP1874117B8/en active Active
- 2006-04-28 SI SI200632410T patent/SI3372281T1/sl unknown
- 2006-04-28 HU HUE17195280 patent/HUE044978T2/hu unknown
- 2006-04-28 DK DK12159082.2T patent/DK2465580T3/en active
- 2006-04-28 EP EP12159079.8A patent/EP2527007B1/en active Active
- 2006-04-28 EP EP16154531.4A patent/EP3045206B2/en active Active
- 2006-04-28 EP EP17195280.7A patent/EP3284520B1/en active Active
- 2006-04-28 DK DK17195280.7T patent/DK3284520T3/da active
- 2006-04-28 KR KR1020077027734A patent/KR101363875B1/ko active IP Right Review Request
- 2006-04-28 LT LTEP17195280.7T patent/LT3284520T/lt unknown
- 2006-04-28 HU HUE16154531A patent/HUE037795T2/hu unknown
- 2006-04-28 BR BRPI0610030A patent/BRPI0610030B8/pt active IP Right Grant
- 2006-04-28 SI SI200631747T patent/SI2465580T1/sl unknown
- 2006-04-28 LT LTEP16154531.4T patent/LT3045206T/lt unknown
- 2006-04-28 ES ES18166621T patent/ES2892304T3/es active Active
- 2006-04-28 LT LTEP18166621.5T patent/LT3372281T/lt unknown
2007
- 2007-10-10 NO NO20075165A patent/NO339525B1/no active Protection Beyond IP Right Term
- 2007-10-10 IL IL186555A patent/IL186555A/en active IP Right Grant
- 2007-10-25 MX MX2011010484A patent/MX312216B/es unknown
- 2007-11-20 MA MA30388A patent/MA29460B1/fr unknown
2008
- 2008-01-24 HK HK08100942.1A patent/HK1107227A1/xx unknown
- 2008-10-08 JP JP2008261344A patent/JP2009079058A/ja active Pending
2011
- 2011-10-23 IL IL215788A patent/IL215788A0/en unknown
2012
- 2012-01-18 US US13/352,686 patent/US8410103B2/en active Active
- 2012-12-18 HK HK12113039.2A patent/HK1172282A1/xx unknown
2013
- 2013-02-08 US US13/763,174 patent/US8778943B2/en active Active
- 2013-03-14 IL IL225207A patent/IL225207A/en active IP Right Review Request
- 2013-03-14 IL IL225206A patent/IL225206A/en active IP Right Grant
- 2013-11-27 CY CY20131101061T patent/CY1115151T1/el unknown
2014
- 2014-03-13 CY CY20141100201T patent/CY1116331T1/el unknown
- 2014-03-14 US US14/211,364 patent/US9051337B2/en active Active
- 2014-05-07 LU LU92446C patent/LU92446I2/xx unknown
- 2014-05-19 FR FR14C0041C patent/FR14C0041I2/fr active Active
- 2014-06-25 CY CY2014024C patent/CY2014024I2/el unknown
- 2014-07-03 NL NL300676C patent/NL300676I2/nl unknown
- 2014-07-09 HU HUS1400039C patent/HUS1400039I1/hu unknown
2015
- 2015-04-30 US US14/700,679 patent/US9273065B2/en active Active
2016
- 2016-01-20 US US15/001,336 patent/US20160137666A1/en not_active Abandoned
- 2016-03-31 US US15/086,616 patent/US20160207939A1/en not_active Abandoned
- 2016-06-29 US US15/196,245 patent/US20160304535A1/en not_active Abandoned
- 2016-08-18 NO NO20161315A patent/NO340111B1/no active Protection Beyond IP Right Term
- 2016-10-11 US US15/290,094 patent/US20170029438A1/en not_active Abandoned
2017
- 2017-02-08 US US15/427,184 patent/US20170145033A1/en not_active Abandoned
- 2017-03-27 NO NO2017010C patent/NO2017010I1/no unknown
- 2017-04-10 US US15/482,896 patent/US20170209454A1/en not_active Abandoned
- 2017-04-27 US US15/498,684 patent/US20170224695A1/en not_active Abandoned
- 2017-04-27 US US15/498,667 patent/US20170224694A1/en not_active Abandoned
- 2017-05-17 US US15/597,343 patent/US20170253616A1/en not_active Abandoned
- 2017-05-18 US US15/598,655 patent/US20170260203A1/en not_active Abandoned
- 2017-05-18 US US15/598,671 patent/US20170267693A1/en not_active Abandoned
- 2017-09-07 US US15/697,847 patent/US20170369509A1/en not_active Abandoned
2018
- 2018-06-19 CY CY20181100633T patent/CY1120345T1/el unknown
- 2018-07-16 HK HK18109159.8A patent/HK1249742A1/zh unknown
- 2018-08-16 HK HK18110519.1A patent/HK1251191A1/zh unknown
2019
- 2019-01-10 US US16/244,441 patent/US20190152990A1/en not_active Abandoned
- 2019-05-01 US US16/400,373 patent/US10927129B2/en active Active
- 2019-08-20 CY CY20191100891T patent/CY1122052T1/el unknown
2020
- 2020-07-09 US US16/924,390 patent/US11267823B2/en active Active
2021
- 2021-05-10 NO NO2021018C patent/NO2021018I1/no unknown
- 2021-06-08 NL NL301109C patent/NL301109I2/nl unknown
- 2021-06-10 FI FIC20210017C patent/FIC20210017I1/fi unknown
- 2021-06-14 HU HUS2100022C patent/HUS2100022I1/hu unknown
- 2021-06-14 HU HUS2100023C patent/HUS2100023I1/hu unknown
- 2021-06-15 LU LU00210C patent/LUC00210I2/en unknown
- 2021-06-16 LT LTPA2021512C patent/LTC2465580I2/lt unknown
- 2021-10-06 CY CY20211100866T patent/CY1124601T1/el unknown
2022
- 2022-01-27 US US17/586,006 patent/US20220213121A1/en not_active Abandoned
2023
- 2023-11-08 NO NO2023042C patent/NO2023042I1/no unknown

Also Published As

Publication number	Publication date
CY1120345T1 (el)	2019-07-10
ES2892304T3 (es)	2022-02-03
HUE044978T2 (hu)	2019-11-28
EP3045206B1 (en)	2018-03-28
NO20161315A1 (no)	2007-11-22
EP2527007A1 (en)	2012-11-28
US20160207939A1 (en)	2016-07-21
US20170224694A1 (en)	2017-08-10
US20140200209A1 (en)	2014-07-17
DK3284520T3 (da)	2019-09-16
US20090318421A1 (en)	2009-12-24
SI3187225T1 (sl)	2022-04-29
ES2906792T3 (es)	2022-04-20
HK1249742A1 (zh)	2018-11-09
AU2006239177B2 (en)	2011-10-20
DK2465580T3 (en)	2014-03-10
HUS2100023I1 (hu)	2021-07-28
MX312216B (en)	2013-08-12
TWI378931B (en)	2012-12-11
BRPI0610030B1 (pt)	2020-09-15
KR101504998B1 (ko)	2015-03-23
BRPI0610030A2 (pt)	2011-10-11
US20130172559A1 (en)	2013-07-04
PL3045206T3 (pl)	2018-08-31
NZ562339A (en)	2011-01-28
EP1874117B1 (en)	2013-08-28
EP3372281B1 (en)	2021-07-07
CA2606282C (en)	2016-04-26
MX302718B (es)	2012-08-27
PT1874117E (pt)	2013-10-17
LTPA2021512I1 (el)	2021-07-12
US8410103B2 (en)	2013-04-02
MA29460B1 (fr)	2008-05-02
EP2465580A1 (en)	2012-06-20
DK3187225T3 (da)	2022-02-28
EA200702080A1 (ru)	2008-04-28
KR101580310B1 (ko)	2016-01-04
US20170260203A1 (en)	2017-09-14
MX2007013351A (es)	2008-01-21
EA014162B1 (ru)	2010-10-29
PT3045206T (pt)	2018-07-05
US11267823B2 (en)	2022-03-08
PL3284520T3 (pl)	2020-01-31
CY1115151T1 (el)	2015-12-09
US20160137666A1 (en)	2016-05-19
US20190284208A1 (en)	2019-09-19
HUS1400039I1 (hu)	2016-08-29
EP3284519A8 (en)	2018-04-18
US20170267693A1 (en)	2017-09-21
SI2465580T1 (sl)	2014-04-30
EP2465580B1 (en)	2013-12-18
PT3284520T (pt)	2019-09-10
KR101363875B1 (ko)	2014-02-21
KR101848819B1 (ko)	2018-04-16
US20120115875A1 (en)	2012-05-10
ES2667868T3 (es)	2018-05-14
JP4295353B2 (ja)	2009-07-15
TW200716635A (en)	2007-05-01
LU92446I2 (fr)	2015-10-29
NO339525B1 (no)	2016-12-27
ES2567197T3 (es)	2016-04-20
KR20130133061A (ko)	2013-12-05
PT2465580E (pt)	2014-02-25
PL2465580T3 (pl)	2014-05-30
KR20160003889A (ko)	2016-01-11
ES2743531T3 (es)	2020-02-19
HUE056603T2 (hu)	2022-02-28
IL225207A (en)	2017-11-30
CA2606282A1 (en)	2006-11-02
US20170253616A1 (en)	2017-09-07
SI1874117T1 (sl)	2014-01-31
EP1874117A1 (en)	2008-01-09
CY1116331T1 (el)	2017-02-08
US9051337B2 (en)	2015-06-09
LTC2465580I2 (el)	2022-10-10
ES2446324T3 (es)	2014-03-07
CY1124601T1 (el)	2022-07-22
EP3284519A1 (en)	2018-02-21
US20150232479A1 (en)	2015-08-20
US20170145033A1 (en)	2017-05-25
NO340111B1 (no)	2017-03-13
EP3187226A1 (en)	2017-07-05
US20190152990A1 (en)	2019-05-23
HK1172282A1 (en)	2013-04-19
HK1251191A1 (zh)	2019-01-25
SI3284520T1 (sl)	2019-10-30
NL301109I1 (nl)	2021-09-15
NO2017010I2 (no)	2017-03-27
US20160304535A1 (en)	2016-10-20
IL225206A (en)	2017-11-30
JP2008540343A (ja)	2008-11-20
EP2527007B1 (en)	2016-03-30
US20220213121A1 (en)	2022-07-07
BRPI0610030B8 (pt)	2022-01-11
LUC00210I2 (el)	2022-10-07
DK3045206T3 (en)	2018-05-22
HK1107227A1 (en)	2008-04-03
IL215788A0 (en)	2011-12-29
US10927129B2 (en)	2021-02-23
US20170369509A1 (en)	2017-12-28
LT3284520T (lt)	2019-09-25
PT3372281T (pt)	2021-10-14
AU2006239177B8 (en)	2012-02-16
HUS2100022I1 (hu)	2021-07-28
HUE037795T2 (hu)	2018-09-28
PL1874117T3 (pl)	2014-01-31
SI3372281T1 (sl)	2021-11-30
FR14C0041I2 (fr)	2015-11-13
EP3187225A1 (en)	2017-07-05
EP3284520A1 (en)	2018-02-21
US9273065B2 (en)	2016-03-01
VN34404A1 (en)	2013-07-25
JP2009079058A (ja)	2009-04-16
ES2437268T3 (es)	2014-01-09
KR20080009733A (ko)	2008-01-29
EP3284520B1 (en)	2019-06-05
FR14C0041I1 (el)	2014-06-27
IL186555A0 (en)	2008-01-20
LT3372281T (lt)	2021-12-10
NO2017010I1 (no)	2017-03-27
IL186555A (en)	2016-10-31
NO2021018I1 (no)	2021-05-10
NL301109I2 (nl)	2021-09-15
KR20140097438A (ko)	2014-08-06
SI3045206T1 (en)	2018-07-31
PL3372281T3 (pl)	2021-12-27
DK1874117T3 (da)	2013-09-23
EP3045206B2 (en)	2023-02-15
WO2006116764A1 (en)	2006-11-02
NO2023042I1 (no)	2023-11-08
ES2667868T5 (es)	2023-06-01
NL300676I2 (el)	2016-10-11
US20170209454A1 (en)	2017-07-27
NO20075165L (no)	2007-11-22
AU2006239177A1 (en)	2006-11-02
US8129385B2 (en)	2012-03-06
FIC20210017I1 (fi)	2021-06-10
EP1874117A4 (en)	2009-12-30
CY1122052T1 (el)	2020-10-14
US8778943B2 (en)	2014-07-15
EP3187225B1 (en)	2022-01-05
LT3045206T (lt)	2018-06-11
EP3045206A1 (en)	2016-07-20
US20170029438A1 (en)	2017-02-02
CY2014024I2 (el)	2015-12-09
DK3372281T3 (da)	2021-09-27
EP3372281A1 (en)	2018-09-12
US20170224695A1 (en)	2017-08-10
EP1874117B8 (en)	2014-03-12
US20200339598A1 (en)	2020-10-29

Publication	Publication Date	Title
CY2014024I1 (el)	2015-12-09	Πολυκυκλικο παραγωγο καρβαμοϋλπυριδονης που εχει ανασταλτικη δραστηριοτητα ιντεγ(κ)ρασης [ενσωματασης] του hiv
IL190879A0 (en)	2008-11-03	Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
EP1790638A4 (en)	2009-10-28	CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITION OF HIV INTEGRASE ACTIVITY
PL1775298T3 (pl)	2013-08-30	Pochodna tienopirazolowa wykazująca aktywność hamowania PDE7
IS7729A (is)	2005-03-08	Bensónaþýridín með PDE 3/4 tálmunarvirkni
EP1854793A4 (en)	2011-01-26	NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
ZA200707227B (en)	2009-08-26	Novel aminopyridine compound with syk inhibitory activity
ZA200803423B (en)	2009-08-26	Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
ES1061285Y (es)	2006-05-16	Estructura de cama extensible
SE0502289L (sv)	2007-04-14	Sängstommesrelaterat arrangemang
FR2866223B1 (fr)	2006-05-19	Article de literie
NO20050645D0 (no)	2005-02-03	Stpo din identitet-betongmobler pa 1,2,3
UA13220S (uk)	2006-12-15	Серветка фільтрувальна